Drug Type AAV based gene therapy |
Synonyms BBP 821, BBP821 |
Target |
Mechanism TSC1 modulators(TSC complex subunit 1 modulators), TSC2 modulators(TSC complex subunit 2 modulators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Tuberous Sclerosis | Preclinical | US | 11 May 2024 |